Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending February 7, 2018. The document serves as a transaction notification regarding share allocations for Persons Discharging Managerial Responsibilities (PDMRs) and Persons Closely Associated (PCAs), specifically Independent Non-Executive Directors.
Key Financial Metrics
The filing does not contain consolidated financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. It exclusively details specific equity transactions.
| Transaction Type | Instrument | Price | Total Volume |
|---|---|---|---|
| Acquisition of Notional Shares | Ordinary Shares (GBP) | £12.78 | 6,807.732 |
| Acquisition of Notional Shares | American Depositary Shares (USD) | $36.20 | 4,293.958 |
Material Changes
The filing reports initial notifications of share acquisitions for the service period of October 1, 2017, to December 31, 2017. There are no material changes to the company's financial position or operations reported in this document.
Guidance, Outlook, and Risks
This filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a regulatory disclosure of director compensation in the form of notional share allocations.
Investor Verification Checklist
- Transaction Nature: Verify that the reported volumes represent "notional" shares allocated as compensation, not open market purchases.
- Service Period: Confirm the allocations correspond to the Q4 2017 service period (Oct 1 - Dec 31, 2017).
- Instrument Types: Note the split between Ordinary Shares (GBP) and American Depositary Shares (USD) based on director preference or location.
- Valuation: Cross-reference the transaction prices (£12.78 and $36.20) with the market price on the transaction date (Feb 7, 2018).